» Articles » PMID: 32565183

Prevalence of Barrett's Esophagus and Performance of Societal screening Guidelines in an Unreferred Primary Care Population of U.S. Veterans

Overview
Date 2020 Jun 23
PMID 32565183
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Less than 10% of patients diagnosed with esophageal adenocarcinoma have a pre-existing Barrett's esophagus (BE) diagnosis, possibly because of suboptimal performance of guidelines. We examined the prevalence of BE in a previously unscreened primary care population and the potential yield of practice BE screening guidelines.

Methods: This was a retrospective analysis of a prospective cross-sectional study of consecutively recruited unreferred patients from primary care clinics who underwent study upper endoscopy. We examined the performance of BE screening guidelines of the European Society of Gastrointestinal Endoscopy (ESGE), British Society of Gastroenterology (BSG), American Society for Gastrointestinal Endoscopy (ASGE), American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), and our own modification of guidelines.

Results: We identified 44 BE cases and 469 control subjects (prevalence, 8.6%). Among 371 patients without GERD symptoms, 25 (6.7%) had BE. The AGA guidelines requiring ≥2 BE risk factors had sensitivity of 100% and specificity of only .2%, whereas ACG, ASGE, ESGE, and BSG guidelines (all requiring GERD first) had low sensitivities (38.6%-43.2%), specificities ranging from 67.4% to 76.5%, and area under the receiver operating curve (AUROC) of .50 to .60. Our 2-pronged approach depending on presence or absence of GERD symptoms but with other risk factors achieved sensitivity of 81.8%, specificity of 51.2%, and AUROC of .66.

Conclusions: Over half of BE cases were without frequent GERD symptoms, but virtually all had at least 1 known BE risk factor. Practice guidelines requiring GERD symptoms have low sensitivity, whereas those not requiring GERD have low specificity. We have proposed a screening guideline with better use of known risk factors.

Citing Articles

Risk Factors for the Development of Barrett's Esophagus and Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Antonios K, Aintabi D, McNally P, Berinstein E, Dutta P, Sampson N Cancer Rep (Hoboken). 2025; 8(3):e70168.

PMID: 40040340 PMC: 11880629. DOI: 10.1002/cnr2.70168.


Cost-effective identification of Barrett's esophagus in the community: A first step towards screening.

Aoki T, Watson D, Bulamu N J Gastroenterol Hepatol. 2024; 39(12):2654-2663.

PMID: 39385742 PMC: 11660199. DOI: 10.1111/jgh.16762.


Prospect and Challenges of Volatile Organic Compound Breath Testing in Non-Cancer Gastrointestinal Disorders.

Zheng W, Pang K, Min Y, Wu D Biomedicines. 2024; 12(8).

PMID: 39200279 PMC: 11351786. DOI: 10.3390/biomedicines12081815.


Patient Factors Associated With Gastroesophageal Reflux Disease Diagnostic Evaluation Strategies: A Retrospective Cohort Study Using Real-World Evidence From a Large U.S. Medical Claims Database.

Vajravelu R, Kolb J, Gellad W, Scott F, Tavakkoli A, Singal A Gastro Hep Adv. 2024; 1(4):563-572.

PMID: 39132063 PMC: 11307463. DOI: 10.1016/j.gastha.2022.03.001.


Barrett's Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study.

Saha B, Verma A, Dierkhising R, Canning R, Kisiel J, Iyer P Clin Gastroenterol Hepatol. 2024; 22(10):2150-2152.e2.

PMID: 38670476 PMC: 11424263. DOI: 10.1016/j.cgh.2024.03.034.


References
1.
. Awareness of family health history as a risk factor for disease--United States, 2004. MMWR Morb Mortal Wkly Rep. 2004; 53(44):1044-7. View

2.
Thrift A . Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?. Dig Dis Sci. 2018; 63(8):1988-1996. DOI: 10.1007/s10620-018-5068-6. View

3.
Kramer J, Fischbach L, Richardson P, Alsarraj A, Fitzgerald S, Shaib Y . Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol. 2012; 11(4):373-381.e1. PMC: 3606681. DOI: 10.1016/j.cgh.2012.11.028. View

4.
Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, Anandasabapathy S . ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019; 90(3):335-359.e2. DOI: 10.1016/j.gie.2019.05.012. View

5.
Wenker T, Tan M, Liu Y, El-Serag H, Thrift A . Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018; 63(11):3112-3119. PMC: 6185782. DOI: 10.1007/s10620-018-5241-y. View